BioLineRx Articles

BioLineRx in-licenses BL-8020, an oral hepatitis C treatment

26 January 2012

BioLineRx inks deal with Compugen

14 December 2011

Ramius makes unsolicited, 60% premium offer to buy Cypress Bioscience for $4.00 per share in cash

20 July 2010

Cypress Bioscience in-licenses novel antipsychotic from BioLineRx for potential $365 million

21 June 2010

Showing 1-4 of 4 articles

Go to beginningPrevious
  • 1
NextGo to end